Reproducibility of right-to-left shunt quantification using transthoracic contrast echocardiography in hereditary haemorrhagic telangiectasia

V. M. M. Vorselaars · S. Velthuis · M. P. Huitema · A. E. Hosman · C. J. J. Westermann · R. J. Snijder · J. J. Mager · M. C. Post

Abstract

Aim Transthoracic contrast echocardiography (TTCE) is recommended for screening of pulmonary arteriovenous malformations (PAVMs) in hereditary haemorrhagic telangiectasia. Shunt quantification is used to find treatable PAVMs. So far, there has been no study investigating the reproducibility of this diagnostic test. Therefore, this study aimed to describe inter-observer and inter-injection variability of TTCE.

Methods We conducted a prospective single centre study. We included all consecutive persons screened for presence of PAVMs in association with hereditary haemorrhagic telangiectasia in 2015. The videos of two contrast injections per patient were divided and reviewed by two cardiologists blinded for patient data. Pulmonary right-to-left shunts were graded using a three-grade scale. Inter-observer and inter-injection agreement was calculated with $\kappa$ statistics for the presence and grade of pulmonary right-to-left shunts.

Results We included 107 persons (accounting for 214 injections) (49.5% male, mean age 45.0 ± 16.6 years). A pulmonary right-to-left shunt was present in 136 (63.6%) and 131 (61.2%) injections for observer 1 and 2, respectively. Inter-injection agreement for the presence of pulmonary right-to-left shunts was 0.96 (95% confidence interval (CI) 0.9–1.0) and 0.98 (95% CI 0.94–1.00) for observer 1 and 2, respectively. Inter-injection agreement for pulmonary right-to-left shunt grade was 0.96 (95% CI 0.93–0.99) and 0.95 (95% CI 0.92–0.98) respectively. There was disagreement in right-to-left shunt grade between the contrast injections in 11 patients (10.3%). Inter-observer variability for presence and grade of the pulmonary right-to-left shunt was 0.95 (95% CI 0.91–0.99) and 0.97 (95% CI 0.95–0.99) respectively.

Conclusion TTCE has an excellent inter-injection and inter-observer agreement for both the presence and grade of pulmonary right-to-left shunts.

Keywords Hereditary haemorrhagic telangiectasia · Pulmonary right-to-left shunt · Transthoracic contrast echocardiography · Pulmonary arteriovenous malformation

Introduction

Transthoracic contrast echocardiography (TTCE) is used to screen for the presence of pulmonary arteriovenous malformations (PAVMs). Over 90% of PAVMs are associated with hereditary haemorrhagic telangiectasia, an inheritable disease characterised by abnormal artery-to-vein connections in the brain, liver or lungs [1, 2]. Most cases are caused by mutations in the ENG and ACVRL1 gene, leading to hereditary haemorrhagic telangiectasia type 1 and type 2 respectively. A rarer mutation is located on the SMAD4 gene. PAVMs are frequently described in all subgroups but more prevalent in hereditary haemorrhagic telangiectasia type 1. In up to 21% of patients PAVMs are associated with severe neurologic complications, such as brain abscesses and ischaemic stroke [3]. Furthermore, PAVMs can result in hypoxaemia, haemoptysis and migraine. Most patients, however, remain asymptomatic before the development of complications, making screening for PAVMs extremely important in all patients with or suspected of hereditary haemorrhagic telangiectasia [1, 4–7].
TTCE represents a functional measurement in which PAVMs are visualised as a pulmonary right-to-left shunt. Pulmonary right-to-left shunt grade on TTCE is a good predictor for the presence of treatable PAVMs on chest computed tomography (CT) [8]. Importantly, only moderate to large right-to-left shunts seem to have clinical implications [3, 8, 9]. The international hereditary haemorrhagic telangiectasia guidelines recommend TTCE as first-choice screenings test for PAVMs. However, the reliability of TTCE is dependent on the reproducibility in the individual patient. Although the inter-observer variability has been described in a few studies, there has been no research evaluating the reproducibility of TTCE. Therefore, we aimed to evaluate both the inter-injection and inter-observer variability of TTCE in this prospective single-centre study.

**Material and methods**

**Study population**

We included all consecutive persons screened for the presence of hereditary haemorrhagic telangiectasia and all consecutive hereditary haemorrhagic telangiectasia patients visiting the outpatient clinic for a regular 5-year follow-up at the Dutch hereditary haemorrhagic telangiectasia centre between February and November 2015. The clinical diagnosis was established according to the Curaçao criteria, which consist of spontaneous and recurrent epistaxis, telangiectasia at characteristic sites, visceral arteriovenous malformations, and a first-degree relative with hereditary haemorrhagic telangiectasia [1]. Genetic testing was offered to all included patients. A definite diagnosis of hereditary haemorrhagic telangiectasia was established in case of three or more Curaçao criteria, or when genetic testing identified the hereditary haemorrhagic telangiectasia causing gene mutation (e.g. ENG, ACVRL1 or SMAD4).

Patients were excluded if TTCE was not complete (e.g. due to intravenous line failure or image storage problems). The study was approved by the local ethics committee (R&D/Z14.059).

**Transthoracic contrast echocardiography**

All TTCEs were performed according to the local clinical protocol. TTCEs were conducted on a Philips IE33 ultrasound instrument (S5-1 transducer; Philips Medical Systems, Best, the Netherlands) or a General Electronic Vivid S6 ultrasound instrument (3S transducer; General Electronic Healthcare, Wauwatosa, The United States).

An intravenous line was inserted in the right antecubital vein, 1 ml blood was drawn and 8 ml physiological saline solution and 1 ml air was added. A second syringe was connected by a bi-directional Luer Lock system. In total, 10 ml agitated saline (containing microbubbles) was created by reverse flushing between the connected syringes [3, 8–10]. The patient was positioned in the left lateral position and 5 ml of agitated saline was injected at rest while projecting the four-chamber apical view. After all microbubbles dissolved, this procedure was repeated.

All TTCE videos were blinded for patient data, numbered and stored in a database. The observers viewed all individual contrast injections in random order to minimise the possibility of bias. Two independent cardiologists (observer 1: VV and observer 2: SV) quantified each shunt.

All right-to-left shunts that clearly originated out of the pulmonary vein were classified as pulmonary right-to-left shunts, and all right-to-left shunts appearing through the septum as cardiac right-to-left shunts. If shunt origin was not visible, a delay of four cardiac cycles was used to distinguish between a pulmonary and cardiac shunt. We considered the TTCE positive for a pulmonary right-to-left shunt if microbubbles appeared in the left atrium after four or more cardiac cycles. The pulmonary right-to-left shunt was graded based on the maximum number of microbubbles present in the left ventricle in one still frame. Right-to-left shunt was graded as 1, 2 or 3 corresponding with 1–29, 30–100 and over 100 microbubbles respectively (Fig. 1 and video 1–3) [3, 8, 10–12].

We reviewed the technical quality of the studies and described image quality as good, sufficient or insufficient. Quantity of contrast in the right ventricle was described as sufficient when opacification of the right ventricle was densely filled (with endocardial lining) [13].

**Chest computer tomography**

We performed a chest CT examination in all patients with a pulmonary right-to-left shunt grade ≥2 in at least one of the injections [3, 14] and used a ≥16-detector CT scanner (Philips Medical Systems, Best, the Netherlands) with a high-resolution algorithm and slice thickness of 1 mm. All CT images were evaluated by an interventional radiologist and a pulmonologist who were blinded to the TTCE results.

**Statistical analysis**

We used descriptive statistics to describe patient characteristics. Continuous variables were reported as mean ± standard deviation. Proportions were given by numbers and corresponding percentages. We measured inter-injection agreement for the presence and grade of a pulmonary right-to-left shunt between the two contrast injections at rest in one patient. Inter-observer agreement was measured for the presence and grade of pulmonary right-to-left shunts between observer 1 and observer 2. We used Cohen’s un-
Fig. 1 Pulmonary right-to-left shunt (RLS) on transthoracic contrast echocardiogram. a No pulmonary RLS. b Pulmonary RLS grade 1. c Pulmonary RLS grade 2. d Pulmonary RLS grade 3.

Table 1 Baseline characteristics

| Number | 107 |
|--------|-----|
| Age    | 45.0 ± 16.6 |
| Male   | 53 (49.5%) |
| Time of TTCE |
| Screening for HHT<sup>a</sup> | 57 (53.3%) |
| Follow-up of pulmonary RLS<sup>b</sup> | 50 (46.7%) |
| Definite HHT<sup>c</sup> | 77 (72.0%) |
| HHT type |
| – Type 1 | 32 (29.9%) |
| – Type 2 | 36 (33.6%) |
| – SMAD4 | 6 (5.6%) |
| – Unknown | 3 (2.8%) |

Data are presented as number (%) or mean ± standard deviation

<sup>a</sup>TTCE made to screen for pulmonary RLS
<sup>b</sup>TTCE made at regular 5 year follow-up
<sup>c</sup>Based on genetic testing or clinical criteria [1]

Results

Between February and November 2015, we used TTCE in 110 patients. After excluding 3 patients (image storage problem $N=2$, intravenous line failure $N=1$), 107 patients (49.5% male, mean age 45.0 ± 16.6 years) were included for further analysis (Tab. 1). Image quality of TTCE was good, sufficient and insufficient in 97 (90.7%), 9 (8.4%) and 1 (0.9%) patients/patient respectively. Quantity of contrast opacification of the right ventricle was sufficient in 197 contrast injections (92.1%). A pulmonary right-to-left shunt...
was present in 136 (63.6%) and 131 (61.2%) injections for observer 1 and 2 respectively. A cardiac right-to-left shunt at rest was present in 3 patients (2.8%) for both observers.

**Inter-injection agreement**

Inter-injection agreement (Tab. 2 and 3) for the presence of pulmonary right-to-left shunt was $\kappa$ coefficient 0.96; 95% CI 0.90–1.00 (observer 1) and $\kappa$ coefficient 0.98; 95% CI 0.94–1.00 (observer 2). Inter-injection agreement for pulmonary right-to-left shunt grade was 0.96; 95% CI 0.93–0.99 (observer 1) and $\kappa$ coefficient 0.95; 95% CI 0.92–0.98 (observer 2). Observer 1 and observer 2 disagreed about right-to-left shunt grade between first and second contrast injection in 8 and 9 patients respectively. This included 11 patients (10.3%) in total, technical quality of the studies showed good image quality in 8 of these patients (72.7%) and difference in contrast opacification of the right ventricle in 6 patients (54.4%). Disagreement between right-to-left shunt grade 1 and 2 occurred in 3 and 5 patients respectively (5 patients (4.7%) in total). CT scans were taken of all 5 patients and showed a very small PAVM
in 1 patient with no possibility for percutaneous treatment. Difference between two injections was never more than one grade. Quantity of contrast in the right ventricle was a predictor for inter-injection disagreement (OR 6.6; 95% CI 1.5–29.8, p = 0.01).

**Inter-observer agreement**

Inter-observer agreement (Tab. 2 and 3) for pulmonary right-to-left shunt presence and grade was κ coefficient 0.95; 95% CI 0.91–0.99 and κ coefficient 0.97; 95% CI 0.95–0.99 respectively.

**Complications**

During placement of an intravenous line, one patient (0.9%) experienced vagal symptoms and an irregular heart rate. Rhythm on TTCE showed atrial fibrillation, which was confirmed with a 12-lead electrocardiogram. During TTCE there were no major complications. One patient (0.9%), with a right-to-left shunt grade 2, reported dizziness in the first hour after TTCE with spontaneous full recovery.

**Discussion**

This is the first study that describes the reproducibility of the detection and quantification of pulmonary right-to-left shunt at screening. However, in 1 patient with no possibility for percutaneous treatment. Difference between two injections was never more than one grade. Quantity of contrast in the right ventricle was a predictor for inter-injection disagreement (OR 6.6; 95% CI 1.5–29.8, p = 0.01). The pulmonary right-to-left shunt grade also predicts the size of PAVMs on CT and the subsequent feasibility of embolisation [8]. This suggests that only moderate and large right-to-left shunts have clinical implications. Therefore, CT can be safely withheld in patients with a grade 1 pulmonary right-to-left shunt reducing radiation exposure for many hereditary haemorrhagic telangiectasia patients [8, 19]. Within 5 years, no treatable PAVMs develop in patients without a pulmonary right-to-left shunt at screening. However, increase in pulmonary right-to-left shunts occurs in approximately 18%, leading to the need for embolisation in 12% of patients with initially non-treatable PAVMs at screening [20].

Although the above data already described the importance of TTCE, reliability of TTCE is based on the inter-observer variability and reproducibility in the individual patient. Many studies already described a high inter-observer agreement (κ coefficient 0.85–0.94) for pulmonary right-to-left shunt detection and, therefore, our results are in line with the previous [11, 12, 21].

This is the first study describing the inter-injection agreement for pulmonary right-to-left shunt quantification since none of the previous studies consecutively performed multiple injections in one single patient. Although not completely comparable, repeated injections for the diagnosis of a cardiac right-to-left shunt have shown to increase the detection of right-to-left shunts due to a high number of false negative injections [13, 22]. Differences in quantification of cardiac right-to-left shunts were mainly based on the technique of provocation, insufficient contrast in the right ventricle and poor image quality. The inter-observer and intra-observer agreements for the detection of a cardiac right-to-left shunt seem much lower (0.77 and 0.82 respectively) in comparison with those found for pulmonary right-to-left shunts [23]. This may be explained by the different mechanisms of both shunts. In contrast to the cardiac right-to-left shunt, the pulmonary right-to-left shunt represents a persistent shunt and therefore no provocation is required to visualise the right-to-left shunt. However, our study confirms the need for sufficient contrast opacification of the right ventricle to obtain a reliable result, as it is shown to be a predictor for inter-injection disagreement (OR 6.6; 95% CI 1.5–29.8, p = 0.01). This confirms the utmost importance of adequately producing and injecting the agitated saline. Obtaining a good acoustic window is essential for reliable right-to-left shunt quantification [24]. Performance of a second contrast injection should therefore be recommended when any doubt on right-to-left shunt grade exists. TTCE may also be used to diagnose a pulmonary right-to-left shunt related to hepatopulmonary syndrome. Although
there are pathophysiological differences, the results of our study may be translated to these patients.

Although this study showed an almost perfect level of inter-injection agreement, it should be emphasised that there was disagreement between the first and second contrast injection in 11 patients (10.3%). This might have clinical implications when treatable PAVMs are missed. Since CT is withheld in patients with a pulmonary right-to-left shunt <2, quantification of a right-to-left shunt grade 1 instead of grade 2 might have consequences. In this study, this occurred in 5 patients (4.7%). CT did not demonstrate treatable PAVMs in any of these patients. This reinforces our previously described recommendation to exclude right-to-left shunts grade 1 from further CT analysis.

Some clinicians have concerns regarding the safety of the contrast injection, especially in patients with a right-to-left shunt. However, the microbubbles in the injected agitated saline are very small and implode easily. Multiple recent studies in patients with and without hereditary haemorrhagic telangiectasia confirm the safety of TTCE and describe only minor and self-resolving side effects such as dizziness and migraine in 0–2% [11, 19, 25, 26]. In line with previous studies, our study showed no severe side effects.

At this moment TTCE is the cornerstone in the diagnostic evaluation of pulmonary right-to-left shunts in the context of hereditary haemorrhagic telangiectasia. However, chest CT remains the gold standard for pre- and post-embolisation evaluation of PAVMs because it provides essential information on the PAVM anatomy (localisation, complexity, size of feeding arteries and aneurysmal sac). Magnetic resonance imaging is also used for PAVM detection. A big advantage compared with chest CT is the avoidance of radiation while the anatomy of the PAVMs can still be demonstrated. Although some studies show promising results, large comparative prospective studies are lacking and the lower spatial resolution (compared with CT) is currently a major limiting factor [27–29].

Limitations

First, this is a single-centre study performed in a tertiary referral hospital that is highly experienced in hereditary haemorrhagic telangiectasia and TTCE, therefore the results may not apply to other centres. Secondly, the level of agreement could be influenced by the presence of only a few patients with a large pulmonary right-to-left shunt. Thirdly, the number of cardiac right-to-left shunts might be underestimated because we only studied the contrast injections at rest focussing on the presence of pulmonary right-to-left shunts. This resulted in a prevalence of 3% compared with 23% in previous studies [30]. Because we used the four-beat rule when the shunt origin could not be visualised, the false positive risk for pulmonary right-to-left shunt is small.

Conclusion

TTCE has an excellent inter-observer and inter-injection agreement for both the presence and grading of pulmonary right-to-left shunts.

Take home message

- Moderate to large pulmonary right-to-left shunts are associated with severe neurologic complications in hereditary haemorrhagic telangiectasia.
- Transthoracic contrast echocardiography is recommended for screening of pulmonary right-to-left shunts, although reproducibility has not been described previously.
- This prospective single-centre study showed that transthoracic contrast echocardiography has an excellent inter-injection and inter-observer agreement for both the presence and grade of pulmonary right-to-left shunts.

Acknowledgements

We would like to thank J. Kelder for his help with the statistical analysis.

Conflict of interest

V.M.M. Vorselaars, S. Velthuis, M.P. Huijtema, A.E. Hosman, C.J.J. Westermann, R.J. Snijder, J.J. Mager and M.C. Post declare that they have no competing interests.

Open Access

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Faughnan ME, Palda VA, Garcia-Tsao G, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet. 2011;48:73–87.
2. Vorselaars VM, Velthuis S, Mager JJ, et al. Direct haemodynamic effects of pulmonary arteriovenous malformation embolisation. Neth Heart J. 2014;22:328–33.
3. Velthuis S, Buscarini E, van Gent MW, et al. Grade of pulmonary right-to-left shunt on contrast echocardiography and cerebral complications: a striking association. Chest. 2013;144:542–8.
4. Faughnan ME, Granton JT, Young LH. The pulmonary vascular complications of hereditary haemorrhagic telangiectasia. Eur Respir J. 2009;33:1186–94.
5. Circo S, Gossage JR. Pulmonary vascular complications of hereditary haemorrhagic telangiectasia. Curr Opin Pulm Med. 2014;20:421–8.
6. Curtin-Ceba R, Swanson KL, Krowka MJ. Pulmonary arteriovenous malformations. Chest. 2013;144:1033–44.
7. van Gent MW, Mager JJ, Snijder RJ, et al. Relation between migraine and size of echocardiographic intrapulmonary right-to-left shunt. Am J Cardiol. 2011;107:1399–404.
8. Velthuis S, Buscarini E, Mager JJ, et al. Predicting the size of pulmonary arteriovenous malformations on chest computed tomography: a role for transthoracic contrast echocardiography. Eur Respir J. 2014;44:150–9.
9. Velthuis S, Buscarini E, Gossage JR, et al. Clinical implications of pulmonary shunting on saline contrast echocardiography. J Am Soc Echocardiogr. 2015;28:255–63.
10. van Gent MW, Post MC, Luermans JG, et al. Screening for pulmonary arteriovenous malformations using transthoracic contrast echocardiography: a prospective study. Eur Respir J. 2009;33:85–91.
11. Gazzaniga P, Buscarini E, Leandro G, et al. Contrast echocardiography for pulmonary arteriovenous malformations screening: does any bubble matter? Eur J Echocardiogr. 2009;10:513–8.
12. Zukotynski K, Chan RP, Chow CM, et al. Contrast echocardiography grading predicts pulmonary arteriovenous malformations on CT. Chest. 2007;132:18–23.
13. Johansson MC, Eriksson P, Guron CW, Dellborg M. Pitfalls in diagnosing PFO: characteristics of false-negative contrast injections during transesophageal echocardiography in patients with patent foramen ovale. J Am Soc Echocardiogr. 2010;23:1136–42.
14. Velthuis S, Vorselaars VM, van Gent MW, et al. Role of transthoracic contrast echocardiography in the clinical diagnosis of hereditary hemorrhagic telangiectasia. Chest. 2013;144:1876–82.
15. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.
16. Shub C, Tajik AJ, Seward JB, Dines DE. Detecting intrapulmonary right-to-left shunt with contrast echocardiography. Observations in a patient with diffuse pulmonary arteriovenous fistulas. Mayo Clin Proc. 1976;51:81–4.
17. Woods TD, Patel A. A critical review of patent foramen ovale detection using saline contrast echocardiography: when bubbles lie. J Am Soc Echocardiogr. 2006;19:215–22.
18. Soliman OI, Geleijnse ML, Meijboom FJ, et al. The use of contrast echocardiography for the detection of cardiac shunts. Eur J Echocardiogr. 2007;8:52–12.
19. Parra JA, Bueno J, Zarauza J, et al. Graded contrast echocardiography in pulmonary arteriovenous malformations. Eur Respir J. 2010;35:1279–85.
20. Vorselaars VM, Velthuis S, Snijder RJ, et al. Follow-up of pulmonary right-to-left shunt in hereditary haemorrhagic telangiectasia. Eur Respir J. 2016;47:1750–7.
21. van Gent MW, Post MC, Snijder RJ, et al. Real prevalence of pulmonary right-to-left shunt according to genotype in patients with hereditary hemorrhagic telangiectasia: a transthoracic contrast echocardiography study. Chest. 2010;138:833–9.
22. Johansson MC, Helgason H, Dellborg M, Eriksson P. Sensitivity for detection of patent foramen ovale increased with increasing number of contrast injections: a descriptive study with contrast transesophageal echocardiography. J Am Soc Echocardiogr. 2008;21:419–24.
23. Cabanes L, Coste J, Derumeaux G, et al. Interobserver and intraobserver variability in detection of patent foramen ovale and atrial septal aneurysm with transesophageal echocardiography. J Am Soc Echocardiogr. 2002;15:441–6.
24. Clarke NR, Timperley J, Kelion AD, Banning AP. Transthoracic echocardiography using second harmonic imaging with Valsalva manoeuvre for the detection of right to left shunts. Eur J Echocardiogr. 2004;5:176–81.
25. Cottin V, Plauchu H, Bayle JY, et al. Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. Am J Respir Crit Care Med. 2004;169:994–1000.
26. Marriott K, Manins V, Forshaw A, et al. Detection of right-to-left atrial communication using agitated saline contrast imaging: experience with 1162 patients and recommendations for echocardiography. J Am Soc Echocardiogr. 2013;26:96–102.
27. Kawai T, Shimohira M, Kan H, et al. Feasibility of time-resolved MR angiography for detecting recanalization of pulmonary arteriovenous malformations treated with embolization with platinum coils. J Vasc Interv Radiol. 2014;25:1339–47.
28. Boussel L, Cernicanu A, Geerts L, et al. 4D time-resolved magnetic resonance angiography for noninvasive assessment of pulmonary arteriovenous malformations patency. J Magn Reson Imaging. 2010;32:1110–6.
29. Schneider G, Uder M, Koehler M, et al. MR angiography for detection of pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. AJR Am J Roentgenol. 2008;190:892–901.
30. Snijder RJ, Luermans JG, de Heij AH, et al. Patent foramen ovale with atrial septal aneurysm is strongly associated with migraine with aura: a large observational study. J Am Heart Assoc. 2016;5:e3771.